SAN ANTONIO — It took decades to get to the GLP-1 breakthrough in obesity treatment. Now, the biopharma industry is clamoring over the field's ...
News
- 'We're good' on weight loss: Biopharmas turn to muscle with new obesity drugs
- SolasCure and U.S. Army Institute of Surgical Research Collaborate for Combat Wound Care
CAMBRIDGE, England & SAN ANTONIO--(BUSINESS WIRE)--SOLASCURE Ltd (“SolasCure”), a biotechnology company developing a novel treatment to transform ...
- Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call ...
... San Antonio, Texas. For more information, visit https://plustherapeutics.com/. Cautionary Statement Regarding Forward-Looking Statements This ...
- BioMark Expands Its Liquid Biopsy Platform with Two Groundbreaking Publications in Breast ...
... San Antonio Breast Cancer Symposium (SABSC), from December 10-13, 2024, San Antonio, Texas. BioMark' Chief Scientific Officer, Jean-François ...
- VP and CFO Edwards James Michael was granted 100,000 shares, increasing direct ... - Quantisnow
SAN ANTONIO,, TX, 78217. (City), (State), (Zip). 2. Issuer Name and Ticker or Trading Symbol bioAffinity Technologies, Inc. [ BIAF ], 5. Relationship ...